rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 6, 1999, Pages 415-426

  Christopher, Frances ^a   Chase, D ^a   Stein, K ^a   Milne, R ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA;

ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DATA BASE; DRUG COST; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; LIFE EXPECTANCY; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; MORTALITY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RASH; THORAX PAIN;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DATA COLLECTION; DEOXYRIBONUCLEASE I; EXPECTORANTS; HUMANS; LUNG DISEASES; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0033394538     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00245.x     Document Type: Article

References (34)

1. 1. Anon. (1996) Summary of Product Characteristics: Pulmozyme. Hertfordshire, Roche Products Limited.
2. 2. Dodge JA, Morison S, Lewis PA, et al. (1997) Incidence, population, and survival of cystic fibrosis in the UK. 1968-95. Archives of Disease in Childhood, 77, 493-496.
3. 3. Ramsey BW. (1996) Management of pulmonary disease in patients with cystic fibrosis. New England Journal of Medicine, 335(3), 179-188.
4. 4. Campbell A, McIntosh N. (1998). Forfar and Arneil's Textbook of Pediatrics. 5th edn. New York. Churchill Livingstone.
5. 5. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. (1990) Recombinant human DNase 1 reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Science, 87, 9188-9192.
6. 6. Perras C, Otten N. (1996) Pulmozyme: Clinical and Economic Impacts. Technology Overview: Pharmaceuticals. Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
7. 7. Tyrrell JC, Legh-Smith JA. (1997) The South & West Region Provision of Health Services for People with Cystic Fibrosis. Part II: Meeting the Need. Bath, Royal United Hospital.
8. 8. Stevens A, Colin-Jones D, Gabbay J. (1995) 'Quick and clean': authoritative health technology assessment for local health care contracting. Health Trends, 27(2), 37-42.
9. 9. BMA. (1998) British National Formulary, no. 36. London, British Medical Association and the Royal Pharmaceutical Society of Great Britain.
10. 10. Guyatt GH, Sackett DL, Cook DJ. (1993) Users guides to the medical literature II. How to use an article about therapy or prevention. Journal of the American Medical Association, 270, 2598-2601.
11. 11. Anon. (1998) The Use of Dornase Alfa in the Management of Cystic Fibrosis. Newcastle upon Tyne, NHS Northern and Yorkshire, Regional Drug Therapeutics Centre.
12. 12. Payne JN, Dixon S, Cooper NJ, McCabe CJ. (1996) The use of DNase in Cystic Fibrosis. Guidance Note for Purchasers 96/01. Sheffield, Trent Institute for Health Services Research (Universities of Leicester, Nottingham and Sheffield).
13. 13. Kearney CE, Wallis CE. (1998) Deoxyribonuclease (DNase) therapy in cystic fibrosis (Cochrane review). In: The Cochrane Library, Issue 4. Oxford, Update Software.
14. 14. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey, et al. (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine, 331(10), 637-642.
15. 15. Hubbard RC, McElvaney NG, Birrer P, et al. (1992) A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. New England Journal of Medicine, 326(12), 812-815.
16. 16. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. (1992) Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. Journal of the American Medical Association, 267(14), 1947-1951.
17. 17. Wilmott RW, Amin RS, Colin AA, et al. (1996) Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. American Journal of Respiratory Critical Care Medicine, 153, 1914-1917.
18. 18. Ramsey BW, Astley SJ, Aitken ML, et al. (1993) Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease, 148(1), 145-151.
19. 19. Laube BL, Auci RM, Shields DE, et al. (1996) Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. American Journal of Respiratory Critical Care Medicine, 153, 752-760.
20. 20. McCoy K, Hamilton S, Johnson C. (1996) Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest, 110(4), 889-895.
21. 21. Shah PI, Bush A, Canny GJ, et al. (1995) Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. European Respiratory Journal, 8, 954-958.
22. 22. Ranasinha C, Assoufi B, Shak S, et al. (1993) Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet, 342, 199-202.
23. 23. Rosenstein BJ, Johnson CAC. (1994) Long-term Follow-up of Phase III rhDNase Trial. Orlando. North American Cystic Fibrosis Conference Abstract, Orlando.
24. 24. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. (1995) Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax, 50(4), 333-338.
25. 25. Shah PL, Scott SF, Geddes DM, Hodson ME. (1995) Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respiratory Medicine, 89, 499-502.
26. 26. Innes JA. (1998) DNase in cystic fibrosis: the challenge of assessing response and maximising benefit (Editorial). Thorax, 53, 1003-1004.
27. 27. Cystic Fibrosis Trust. (1994). Guidelines for the Treatment of Cystic Fibrosis with Dornase Alfa (Pulmozyme) London, CF Trust.
28. 28. Ledson MJ, Wahbi Z, Convery RP, Cowperthwaite C, Heaf DP, Walshaw MJ. (1998) Targeting of dornase alpha therapy in adult cystic fibrosis. Journal of the Royal Society of Medicine, 91(7), 360-364.
29. 29. Bush A. (1998) Early treatment with dornase alfa in cystic fibrosis: what are the issues? [editorial]. Pediatric Pulmonology, 25(2), 79-82.
30. 30. Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A. (1997) Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatric Pulmonology, 23(4), 243-248.
31. 31. Kerem E, Reisen J, Corey M, et al. (1992) Prediction of mortality in patients with cystic fibrosis. New England Journal of Medicine, 326(18), 1187-1191.
32. 32. Konstan MW, Byard PJ, Hoppel CL, et al. (1995) Effect of high-dose Ibuprofen in patients with cystic fibrosis. New England Journal of Medicine, 332(13), 848-854.
33. 33. HM Treasury. (1997). Appraisal and Evaluation in Central Government: Treasury Guidance. London: The Stationary Office.
34. 34. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. (1997). Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press.